In Segment A, members will receive distinctive doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants might be enrolled on the determined monotherapy dosign program. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 will likely be supplied as "add-on" therapy. In Segment C, https://samuely110jvf3.aboutyoublog.com/profile